NET Cancer Day
May 19 2014
Ron Hollander, Executive Director of the Caring for Carcinoid Foundation’s (CFCF) is pleased to announce the Foundation’s sponsorship of its first clinical trial. Using a new approach for delivering radiation to neuroendocrine tumors (NET), the project is designed to study a potentially safer and more effective form of Peptide Receptor Radionuclide Therapy (PRRT) for NET patients. The project will be carried out at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and will use this new approach for both treatment with the radionuclide, Lutetium-177 and imaging with the radionuclide, Gallium-68. Thanks to the generous support of our donors, we are thrilled to have this opportunity to test this approach in the hopes that it can lead to an improved treatment option for patients living with neuroendocrine cancers in the United States and beyond. To find out more, please visit the blog of CFCF’s Director of Research, Lauren Erb. Lauren’s blog.
This article was submitted by the Caring for Carcinoid Foundation.